Diagnostic value of detection of serum G-17，sB7-H3，and DKK1 for early gastric cancer

doi:10.3760/cma.j.cn371439-20240304-00083

Abstract

Abstract:

Objective To explore the diagnostic value of detection of serum gastrin-17 (G-17),soluble B7-H3 (sB7-H3),and Dickkopf-1 (DKK1) in early gastric cancer (EGC). Methods A total of 95 patients with EGC admitted to the Hospital of 81st Group Army of the Chinese People's Liberation Army from April 2021 to April 2023 were selected as the EGC group,95 gastritis patients as the gastritis group,and 95 healthy individuals as the control group. The serum levels of G-17,sB7-H3,and DKK1 were compared among the three groups of subjects,and serum G-17,sB7-H3 and DKK1 levels of patients with different pathological characteristics in EGC group were also compared. Receiver operator characteristic (ROC) curve was applied to analyze the diagnostic value of serum G-17,sB7-H3,and DKK1 levels for EGC. Multivariate logistic regression was applied to analyze the risk factors of EGC. Results The proportions of Helicobacter pylori infection in the control group,gastritis group,and EGC group were 20.00% (19/95),35.79% (34/95),and 61.05% (58/95),respectively,with a statistically significant difference (χ²=34.26,P<0.001). The serum G-17 levels were (6.98±0.55),(8.39±0.95),and (9.46±1.38) pmol/L,respectively,with a statistically significant difference (F=141.82,P<0.001). The levels of sB7-H3 were (18.86±1.64),(20.34±2.16),(22.44±2.62) ng/ml,respectively,with a statistically significant difference (F=64.86,P<0.001). The levels of DKK1 were (12.87±1.96),(14.75±2.09),(6.93±2.24) ng/ml,respectively,with a statistically significant difference (F=88.95,P<0.001). Pairwise comparison showed that the proportion of Helicobacter pylori infection in the control group,gastritis group and EGC group increased in turn,and the levels of serum G-17,sB7-H3 and DKK1 increased in turn (all P<0.05). There were no significant difference in age and gender between EGC patients with different serum G-17,sB7-H3 and DKK1 levels (all P>0.05),and there were statistically significant differences in tumor diameter (χ²=5.74,P=0.017; χ²=4.98,P=0.026; χ²=5.74,P=0.017),tumor invasion (χ²=10.94,P=0.001; χ²=16.16,P<0.001; χ²=21.16,P<0.001),lymph node metastasis (χ²=6.75,P=0.009; χ²=10.68,P=0.001; χ²=4.74,P=0.029) and differentiation type (χ²=7.00,P=0.008; χ²=4.26,P=0.039; χ²=27.18,P<0.001). ROC curve analysis showed that the area under the curve (AUC) of G-17,sB7-H3 and DKK1 in the diagnosis of EGC was 0.825,0.763 and 0.785,respectively. The AUC of the combined detection of the three indicators was 0.933,which was better than that of the three separate tests (Z=3.22, P=0.001; Z=4.94, P<0.001; Z=4.53, P<0.001). Multivariate logistic regression analysis showed that the levels of G-17(OR=3.82,95%CI: 1.73-8.44, P<0.001), sB7-H3(OR=3.96, 95%CI:1.75-8.96, P<0.001), DKK1(OR=3.85, 95%CI:1.77-8.41,P<0.001) were the independent risk factors of EGC. Conclusion Serum G-17,sB7-H3,and DKK1 have certain auxiliary diagnostic value of three indexes for EGC,and the combined detection value is higher.

Key words: Stomach neoplasms, Gastrins, Soluble B7-H3, Dickkopf-1, Diagnosis

Liu Wenhui, Yin Ping, Qi Jie. Diagnostic value of detection of serum G-17，sB7-H3，and DKK1 for early gastric cancer[J]. Journal of International Oncology, 2024, 51(8): 498-503.

Figures/Tables 4

References 21

[1]	Harada K, Zhao MN, Shanbhag N, et al. Palliative care for advanced gastric cancer[J]. Expert Rev Anticancer Ther, 2020, 20(7): 575-580. DOI: 10.1080/14737140.2020.1781620.
[2]	Chiarello MM, Fico V, Pepe G, et al. Early gastric cancer: a challenge in western countries[J]. World J Gastroenterol, 2022, 28(7): 693-703. DOI: 10.3748/wjg.v28.i7.693.
[3]	Oo SL, Venkatesh S, Karthikeyan V, et al. Highly sensitive and cost-effective portable sensor for early gastric carcinoma diagnosis[J]. Sensors (Basel), 2021, 21(8): 2639. DOI: 10.3390/s21082639.
[4]	Lin ZB, Bian HQ, Chen CY, et al. Application of serum pepsinogen and carbohydrate antigen 72-4 (CA72-4) combined with gastrin-17 (G-17) detection in the screening, diagnosis, and evaluation of early gastric cancer[J]. J Gastrointest Oncol, 2021, 12(3): 1042-1048. DOI: 10.21037/jgo-21-254. pmid: 34295555
[5]	张静, 张伟涛, 宁永忠. 非肌层浸润性膀胱癌患者血清Irisin、sB7-H3、A/G及与临床病理特征和预后的关系[J]. 国际检验医学杂志, 2023, 44(19): 2337-2342, 2348. DOI: 10.3969/j.issn.1673-4130.2023.19.007.
[6]	Shi T, Zhang YP, Wang Y, et al. DKK1 promotes tumor immune evasion and impedes anti-PD-1 treatment by inducing immunosuppressive macrophages in gastric cancer[J]. Cancer Immunol Res, 2022, 10(12): 1506-1524. DOI: 10.1158/2326-6066.CIR-22-0218. pmid: 36206576
[7]	中国抗癌协会胃癌专业委员会. CACA胃癌整合诊治指南(精简版)[J]. 中国肿瘤临床, 2022, 49(14): 703-710. DOI: 10.12354/j.issn.1000-8179.2022.20220712.
[8]	Wu P, Wang JN, Mao XY, et al. PDCD4 regulates apoptosis in human peritoneal mesothelial cells and promotes gastric cancer peritoneal metastasis[J]. Histol Histopathol, 2021, 36(4): 447-457. DOI: 10.14670/HH-18-305. pmid: 33442866
[9]	杨娅, 宁晓飞, 李炳亮, 等. 原花青素通过诱导活性氧产生介导抗SNU-1胃癌细胞株的作用机制研究[J]. 国际肿瘤学杂志, 2022, 49(5): 257-262. DOI: 10.3760/cma.j.cn371439-20220210-00048.
[10]	唐琳, 相明月, 张建波, 等. 卡瑞利珠单抗联合阿帕替尼及化疗二线或以上治疗HER-2阴性晚期胃癌的临床疗效及安全性[J]. 国际肿瘤学杂志, 2022, 49(5): 276-281. DOI: 10.3760/cma.j.cn371439-20220111-00051.
[11]	Shen HZ, Xiong KW, Wu XY, et al. The diagnostic value of serum gastrin-17 and pepsinogen for gastric cancer screening in eastern China[J]. Gastroenterol Res Pract, 2021, 2021: 6894248. DOI: 10.1155/2021/6894248.
[12]	Dondov G, Amarbayasgalan D, Batsaikhan B, et al. Diagnostic performances of pepsinogens and gastrin-17 for atrophic gastritis and gastric cancer in Mongolian subjects[J]. PLoS One, 2022, 17(10): e0274938. DOI: 10.1371/journal.pone.0274938.
[13]	Li YJ, Zhao Y, Li Y, et al. Gastrin-17 induces gastric cancer cell epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway[J]. J Physiol Biochem, 2021, 77(1): 93-104. DOI: 10.1007/s13105-020-00780-y. pmid: 33625675
[14]	Zhao WX, Liu ZF, Li XL, et al. Correlations of serum homocysteine, VEGF and gastrin 17 with gastric cancer and precancerous lesions[J]. Eur Rev Med Pharmacol Sci, 2019, 23(10): 4192-4198. DOI: 10.26355/eurrev_201905_17922.
[15]	Huang LL, Zhou Y, Sun QW, et al. Evaluation of the role of soluble B7-H3 in association with membrane B7-H3 expression in gastric adenocarcinoma[J]. Cancer Biomark, 2022, 33(1): 123-129. DOI: 10.3233/CBM-210178.
[16]	陈忠, 朱燕, 毛飞. 胃癌患者血清sB7-H3检测的临床意义[J]. 中国实验诊断学, 2022, 26(11): 1665-1668. DOI: 10.3969/j.issn.1007-4287.2022.11.018.
[17]	Li J, Gao Y, Yue WT. The clinical diagnostic and prognostic value of dickkopf-1 in cancer[J]. Cancer Manag Res, 2020, 12: 4253-4260. DOI: 10.2147/CMAR.S254596. pmid: 32606922
[18]	Li J, Zhang YQ, Ye FZ, et al. DKK1 promotes epithelial-mesenchymal transition and cisplatin resistance in gastric cancer via activation of the PI3K/AKT pathway[J]. Cancers (Basel), 2023, 15(19): 4756. DOI: 10.3390/cancers15194756.
[19]	Wang Y, Cui DQ, Li D, et al. Clinical value on combined detection of serum CA724, DKK1, and TK1 in diagnosis of gastric cancer[J]. J Oncol, 2022, 2022: 6941748. DOI: 10.1155/2022/6941748.
[20 ]	朱进华, 冯祥, 华召来, 等. 胃癌高发地区40-69岁人群幽门螺旋杆菌感染与胃部疾病关联分析[J]. 中华肿瘤防治杂志, 2023, 30(13): 765-772. DOI: 10.16073/j.cnki.cjcpt.2023.13.01.
[21]	Li Y, Hahn AI, Laszkowska M, et al. Clinicopathological charac-teristics and risk factors of young-onset gastric carcinoma: a systematic review and meta-analysis[J]. Clin Transl Gastroenterol, 2024, 15(6): e1. DOI: 10.14309/ctg.0000000000000714.

指标	对照组（n=95）	胃炎组（n=95）	EGC组（n=95）	F/χ²值	P值
年龄（岁）	56.44±9.28	56.53±9.65	56.88±9.37	0.06	0.944
性别
男	32（33.68）	31（32.63）	30（31.58）	0.10	0.953
女	63（66.32）	64（67.37）	65（68.42）	0.10	0.953
吸烟史
有	38（40.00）	35（36.84）	36（37.89）	0.21	0.901
无	57（60.00）	60（63.16）	59（62.11）	0.21	0.901
饮酒史
有	46（48.42）	42（44.21）	45（47.37）	0.37	0.833
无	49（51.58）	53（55.79）	50（52.63）	0.37	0.833
幽门螺杆菌感染
有	19（20.00）	34（35.79）^a	58（61.05）^ab	34.26	<0.001
无	76（80.00）	61（64.21）^a	37（38.95）^ab	34.26	<0.001
G-17（pmol/L）	6.98±0.55	8.39±0.95^a	9.46±1.38^ab	141.82	<0.001
sB7-H3（ng/ml）	18.86±1.64	20.34±2.16^a	22.44±2.62^ab	64.86	<0.001
DKK1（ng/ml）	12.87±1.96	14.75±2.09^a	16.93±2.24^ab	88.95	<0.001

临床病理特征	例数	G-17				sB7-H3				DKK1
临床病理特征	例数	高水平组（n=48）	低水平组（n=47）	χ²值	P值	高水平组（n=47）	低水平组（n=48）	χ²值	P值	高水平组（n=48）	低水平组（n=47）	χ²值	P值
年龄（岁）
≤60	44	23（52.27）	21（47.73）	0.10	0.752	20（45.45）	24（54.55）	0.53	0.467	26（59.09）	18（40.91）	2.41	0.121
>60	51	25（49.02）	26（50.98）	0.10	0.752	27（52.94）	24（47.06）	0.53	0.467	22（43.14）	29（56.86）	2.41	0.121
性别
男	30	18（60.00）	12（40.00）	1.57	0.210	19（63.33）	11（36.67）	3.37	0.066	16（53.33）	14（46.67）	0.14	0.710
女	65	30（46.15）	35（53.85）	1.57	0.210	28（43.08）	37（56.92）	3.37	0.066	32（49.23）	33（50.77）	0.14	0.710
肿瘤最大径（cm）
≥5	58	35（60.34）	23（39.66）	5.74	0.017	34（58.62）	24（41.38）	4.98	0.026	35（60.34）	23（39.66）	5.74	0.017
<5	37	13（35.14）	24（64.86）	5.74	0.017	13（35.14）	24（64.86）	4.98	0.026	13（35.14）	24（64.86）	5.74	0.017
肿瘤浸润
有	62	39（62.90）	23（37.10）	10.94	0.001	40（64.52）	22（35.48）	16.16	<0.001	42（67.74）	20（32.26）	21.16	<0.001
无	33	9（27.27）	24（72.73）	10.94	0.001	7（21.21）	26（78.79）	16.16	<0.001	6（18.18）	27（81.82）	21.16	<0.001
淋巴结转移
有	57	35（61.40）	22（38.60）	6.75	0.009	36（63.16）	21（36.84）	10.68	0.001	34（59.65）	23（40.35）	4.74	0.029
无	38	13（34.21）	25（65.79）	6.75	0.009	11（28.95）	27（71.05）	10.68	0.001	14（36.84）	24（63.16）	4.74	0.029
分化类型
低/中分化	61	37（60.66）	24（39.34）	7.00	0.008	35（57.38）	26（42.62）	4.26	0.039	43（70.49）	18（29.51）	27.18	<0.001
高分化	34	11（32.35）	23（67.65）	7.00	0.008	12（35.29）	22（64.71）	4.26	0.039	5（14.71）	29（85.29）	27.18	<0.001

变量	β值	SE值	Wald χ²值	OR值	95%CI	P值
幽门螺杆菌感染	0.89	0.47	3.62	2.43	0.97~6.05	0.057
G-17	1.33	0.41	10.93	3.82	1.73~8.44	<0.001
sB7-H3	1.38	0.42	10.87	3.96	1.75~8.96	<0.001
DKK1	1.35	0.40	11.49	3.85	1.77~8.41	<0.001